Pregnancy, delivery, and the postpartum period in women with hereditary angioedema with C1 inhibitor deficiency: a review of current management approaches and analysis of survey data from Belarusian patien

Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) requires particular attention during pregnancy because of the unpredictable effects of hormonal changes on disease activity, the risk of potentially severe attacks, and the need to select treatment that is safe for both the mother and the fetus. This article summarizes current evidence from the literature and up-to-date recommendations for the management of women with C1-INH-HAE during pregnancy, delivery, and breastfeeding. The available evidence demonstrates that HAE is not a contraindication to pursuing reproductive plans. In addition, we present the results of a survey of 8 Belarusian women with C1-INH-HAE who had a total of 19 pregnancies, 14 of which resulted in delivery. Disease course in this cohort was highly variable: an increase in attack frequency was reported in 6/14 (42,9%) of pregnancies, near-complete cessation of attacks in 5/14 (35.7%), and no substantial change in 3/14 (21,4%); moreover, the course of the disease could differ between successive pregnancies. In one case, an abdominal HAE attack was misdiagnosed as an acute surgical condition, resulting in appendectomy at 26 weeks of gestation, followed by pregnancy loss. Most deliveries occurred vaginally (12/14, 85,7%), while HAE attacks within the first 72 hours after delivery occurred in 3/14 cases (21,4%). The current approaches to the treatment and prophylaxis of C1-INH-HAE presented in this article may serve as a practical guide for healthcare professionals involved in the management of patients with HAE, facilitating timely diagnosis and treatment of attacks, rational selection of therapy, and improvement of patients’ quality of life.

1. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update / M. Maurer [et al.] // Allergy. – 2022. – Vol. 77, iss. 7. – P. 1961-1990.

2. Burden of illness in hereditary angioedema: a conceptual model / A. Bygum, E. Aygören-Pürsün, K. Beusterien [et al.] // Acta Dermato-Venereologica. – 2015. – Vol. 95, № 6. – P. 706-710.

3. Hereditary angioedema: epidemiology, management, and role of icatibant / A. Ghazi, J.A. Grant // Biologics. – 2013. – Vol. 7. – P. 103-113.

4. Hereditary angioedema with normal C1 inhibitor: four types and counting / B.L. Zuraw // J. Allergy Clin. Immunol. – 2018. – Vol. 141, № 3. – P. 884-885.

5. The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews / M. Jean-Baptiste, R. Itzler, S. Prusty, D. Supina, M.L. Martin // Orphanet J. Rare Dis. – 2022. – Vol. 17, № 1. – P. 232. https://doi.org/10.1186/s13023-022-02360-3.

6. Guryanova I.E., Zharankova Yu.S., Skopovets E.Ya., Vertelko V.R., Lyubushkin A.V., Korosteleva L.B., Polyakova E.A., Aleshkevich S.N., Migas A.A., Tikhonova E.S., Salivonchik A.P., Belevtsev M.V. Registry of patients with hereditary angioedema in the Republic of Belarus // Hematology. Transfusiology. Eastern Europe. – 2022. – No. 3. – P. 271–284.

7. Hereditary and acquired angioedema: heterogeneity of pathogenesis and clinical phenotypes / M. Bova, G. De Feo, R. Parente // Int. Arch. Allergy Immunol. – 2018. – Vol. 175, № 3. – P. 126-135. https://doi.org/10.1159/000486312.

8. Hereditary angioedema: an update on causes, manifestations and treatment / H.J. Longhurst, K. Bork // Br. J. Hosp. Med. (Lond.). – 2019. – Vol. 80, № 7. – P. 391-398.

9. Case report: Hereditary angioedema in pregnancy / A.D. Jakes, I. Thorne, J. Guly, S. Kiani-Alikhan, A. Banerjee // Obstet. Med. – 2021. – Vol. 14, № 3. – P. 177-180. https://doi.org/10.1177/1753495X20958225.

10. Disease expression in women with hereditary angioedema / L. Bouillet, H. Longhurst, I. Boccon-Gibod [et al.] // Am. J. Obstet. Gynecol. – 2008. – Vol. 199, № 5. – P. 484.e1-484.e4.

11. The hereditary angioedema triggered by estrogen: systematic review / J.E. Peixoto da Costa, J.P. Oliveira Lopes, B.D. Souto [et al.] // Arch. Clin. Biomed. Res. – 2019. – Vol. 3. – P. 343-356.

12. Experience with intravenous plasma-derived C1-inhibitor in pregnant women with hereditary angioedema: a systematic literature review / J.P. Brooks, C. Radojicic, M.A. Riedl, S.D. Newcomer, A. Banerji, F.I. Hsu // J. Allergy Clin. Immunol. Pract. – 2020. – Vol. 8, № 8. – P. 2645-2652.e4. https://doi.org/10.1016/j.jaip.2020.03.009.

13. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey / I. Czaller, B. Visy, D. Csuka [et al.] // Eur. J. Obstet. Gynecol. Reprod. Biol. – 2010. – Vol. 152, № 1. – P. 44-49.

14. Characterization of acute hereditary angioedema attacks during pregnancy and breast feeding and their treatment with C1 inhibitor concentrate / I. Martinez-Saguer, E. Rusicke, E. Aygören-Pürsün [et al.] // Am. J. Obstet. Gynecol. – 2010. – Vol. 203, № 2. – P. 131.e1-131.e4.

15. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency / T. Gonzalez-Quevedo, J.I. Larco, C. Marcos [et al.] // J. Investig. Allergol. Clin. Immunol. – 2016. – Vol. 26, № 3. – P. 161-167.

16. Safety of medications for hereditary angioedema during pregnancy and lactation / A. Yeich, W. Elhatw, Z. Ashoor, K. Park, T. Craig // Expert Opin. Drug Saf. – 2023. – Vol. 22, № 1. – P. 17-24.

17. Angioedema due to bradykinin dysregulation / M. Cicardi, B.L. Zuraw // J. Allergy Clin. Immunol. Pract. – 2018. – Vol. 6, № 4. – P. 1132-1141. https://doi.org/10.1016/j.jaip.2018.04.022.

18. The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities / D.O. Vázquez, P. Giavina-Bianchi, D. Josviack [et al.] // World Allergy Organ. J. – 2026. – Vol. 19, № 5. – P. 101335. https://doi.org/10.1016/j.waojou.2026.101335.

19. Danazol [Электронный ресурс] / Drugs.com. – Режим доступа: https://www.drugs.com/danazol.html. – Дата доступа: 12.08.2026.

20. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency / T. Caballero, H. Farkas, L. Bouillet [et al.] // J. Allergy Clin. Immunol. – 2012. – Vol. 129, № 2. – P. 308-320.

21. Treatment of hereditary angioedema attacks with icatibant and recombinant C1 inhibitor during pregnancy / R. Hakl, P. Kuklínek, I. Krčmová, P. Králíčková, T. Freiberger, P. Janků, M. Vlková, J. Litzman // Journal of Clinical Immunology. – 2018. – Vol. 38, № 7. – P. 810-815. https://doi.org/10.1007/s10875-018-0553-4.

22. Is icatibant safe for the treatment of hereditary angioedema during pregnancy? / D.V. Šimac, T. Štimac, S. Novak // Curr. Allergy Asthma Rep. – 2022. – Vol. 22, № 10. – P. 135-140. https://doi.org/10.1007/s11882-022-01040-3.

23. Management of pregnancy, delivery and breast-feeding in hereditary angioedema: an analysis of 15 pregnancies with conventional treatment approaches and a case of lanadelumab use / M. Casanova, M.C. Brüggen, W.A. Wuillemin, C. Weber-Chrysochoou // Orphanet J. Rare Dis. – 2026. – Vol. 21, № 1. – P. 111. https://doi.org/10.1186/s13023-026-04280-y.

24. Berotralstat during pregnancy in a patient with hereditary angioedema / A. Zanichelli, D. Scaramuzzi, L. Dagna // J. Investig. Allergol. Clin. Immunol. – 2026. – Epub ahead of print. https://doi.org/10.18176/jiaci.1163.

25. Successful pregnancy outcome in a hereditary angioedema patient with previous pregnancy losses: a proposed delivery plan / T. Satnarine, A. Xavier de Almeida, J. Gebbia, G. Kleiner, M. Gans // Cureus. – 2024. – Vol. 16, № 2. – P. e54939. https://doi.org/10.7759/cureus.54939.

26. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema / P.J. Busse, S.C. Christiansen, M.A. Riedl [et al.] // J. Allergy Clin. Immunol. Pract. – 2021. – Vol. 9, № 1. – P. 132-150.e3.

27. Pregnancy in women with hereditary angioedema due to C1-inhibitor deficiency: results from the ITACA cohort study on outcome of mothers and children with in utero exposure to plasma-derived C1-inhibitor / P. Triggianese, R. Senter, A. Petraroli [et al.] // Front. Med. (Lausanne). – 2022. – Vol. 9. – P. 930403. https://doi.org/10.3389/fmed.2022.930403.

28. Diagnosis and treatment of patients with primary immunodeficiencies (adult population): clinical protocol [Electronic resource] / Ministry of Health of the Republic of Belarus. – Approved by Resolution No. 102 of the Ministry of Health of the Republic of Belarus dated 11 October 2022. – Available at: https://minzdrav.gov.by/. – Accessed: 19 August 2026.